Skip to content
2000
Volume 22, Issue 8
  • ISSN: 1871-5265
  • E-ISSN: 2212-3989

Abstract

To date, no accepted therapy exists for treating the emerging infectious disease nCOVID-19 in a safe and effective way. Although various treatment options are under in the developing phase around the world, several studies concerning convalescent plasma (CP) from recovered patients reported promising effects against nCOVID-19 infected critically ill patients nowadays. The therapy showed very few adverse effects, and it helps diminish the viral load when administered at an early stage of infection. Convalescent plasma appears safe for critically ill nCOVID-19 patients by decreasing serum viral loads, and most cases are virus negative after CP transfusion. The convalescent plasma can be good as it has already been utilized to treat previous pandemics like Ebola, influenza, and SARS-CoV infection. In this review article, we pointed out CP's background, rationality, mechanisms, and safety outcomes to treat nCOVID-19 infected patients.

Loading

Article metrics loading...

/content/journals/iddt/10.2174/1871526522666220425103031
2022-12-01
2025-03-24
Loading full text...

Full text loading...

/content/journals/iddt/10.2174/1871526522666220425103031
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test